| Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis. | 2024 | Rheumatic & Musculoskeletal Diseases |
| Disease-modifying antirheumatic drugs in the treatment of autoimmune inner ear disease: a systematic review and meta-analysis of auditory and vestibular outcomes. | 2023 | Otology & Neurotology |
| Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis. | 2023 | Scientific Reports |
| Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. | 2023 | The Cochrane Database of Systematic Reviews |
| Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies. | 2023 | JAMA Dermatology |
| Therapeutic equivalence of biosimilar and reference biologic drugs in rheumatoid arthritis: a systematic review and meta-analysis. | 2023 | JAMA Network Open |
| Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review. | 2023 | Pediatric Rheumatology Online Journal |
| Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: a meta-analysis. | 2023 | Frontiers in Pharmacology |
| Disease-modifying antirheumatic drugs in the treatment of autoimmune inner ear disease: a systematic review and meta-analysis of auditory and vestibular outcomes. | 2023 | Otology & Neurotology |
| Risk of hospitalization for serious infection after initiation of ustekinumab or other biologics in patients with psoriasis or psoriatic arthritis. | 2022 | Arthritis Care & Research |
| Biologic disease-modifying antirheumatic drugs for preventing radiographic progression in psoriatic arthritis: a systematic review and network meta-analysis. | 2022 | Pharmaceutics |
| Infection risk in psoriatic patients receiving tumour necrosis factor inhibitors: a 20-year systematic review and meta-analysis of randomized controlled trials. | 2022 | Journal of the European Academy of Dermatology and Venereology |
| Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis. | 2022 | The Cochrane Database of Systematic Reviews |
| Efficacy and safety of biological agents for the treatment of pediatric patients with psoriasis: a Bayesian analysis of six high-quality randomized controlled trials. | 2022 | Frontiers in Immunology |
| Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials. | 2022 | Seminars in Arthritis and Rheumatism |
| Adherence and persistence to biological drugs for psoriasis: systematic review with meta-analysis. | 2022 | Journal of Clinical Medicine |
| A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: an evidence gap in precision medicine. | 2022 | Clinical and Experimental Rheumatology |
| Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. | 2022 | The Journal of Dermatological Treatment |
| Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. | 2022 | Modern Rheumatology |
| Biologics for pediatric psoriasis: a systematic review and meta-analysis. | 2022 | Pediatric Dermatology |
| Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. | 2021 | Cochrane Database of Systematic Reviews |
| Management of diffuse alveolar hemorrhage in the hematopoietic stem cell transplantation population: a systematic review. | 2021 | Pharmacotherapy |
| Short-term efficacy of biologic therapies in moderate-to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis. | 2021 | Dermatology and therapy |
| Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data. | 2021 | Dermatology and Therapy |
| Efficacy and safety of anti-tnfα therapy for uveitis associated with juvenile idiopathic arthritis: a systematic review and meta-analysis. | 2021 | Rheumatology and Therapy |
| Biologic drug survival in psoriasis: a systematic review & comparative meta-analysis. | 2021 | Frontiers in Medicine |
| Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. | 2021 | Expert Review of Clinical Immunology |
| Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome. | 2020 | Rheumatic & Musculoskeletal Diseases |
| Drug survival of biologics in treating ankylosing spondylitis: a systematic review and meta-analysis of real-world evidence. | 2020 | BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene therapy |
| Effectiveness and safety of systemic therapy for psoriasis in older adults: a systematic review. | 2020 | Journal of Cutaneous Medicine and Surgery |
| Reduction of biologics in rheumatoid arthritis: a systematic review and meta-analysis. | 2020 | Rheumatology International |
| The benefit–risk balance for biological agents in juvenile idiopathic arthritis: a meta-analysis of randomized clinical trials. | 2020 | Rheumatology |
| FDA approved biologics: can etanercept and ustekinumab be considered a first-line systemic therapy for pediatric/adolescents in moderate to severe psoriasis? A systematic review. | 2020 | Cureus |
| Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis. | 2020 | Journal of American Academy of Dermatology |
| Impact of TNF-α inhibitors on body weight and BMI: a systematic review and meta-analysis. | 2020 | Frontiers in Pharmacology |
| Real-world evidence on etanercept biosimilar SB4 in etanercept-naïve or switching patients: a systematic review. | 2019 | Rheumatology and Therapy |
| Paradoxical hidradenitis suppurativa in patients receiving TNF-α inhibitors: case series, systematic review, and case meta-analysis. | 2019 | Dermatology |
| Biologic therapies targeting the interleukin (IL)-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. | 2019 | Journal of the European Academy of Dermatology and Venereology |
| Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: a systematic review and network meta-analysis. | 2019 | Seminars in Arthritis and Rheumatism |
| Anti-TNF drugs for chronic uveitis in adults-a systematic review and meta-analysis of randomized controlled trials. | 2019 | Frontiers in Medicine |
